These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 36035124)

  • 21. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis.
    Wu S; Wu F; Ding Y; Hou J; Bi J; Zhang Z
    Sci Rep; 2016 Sep; 6():33386. PubMed ID: 27633274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes.
    Li M; Zhao Z; Qin G; Chen L; Lu J; Huo Y; Chen L; Zeng T; Xu M; Chen Y; Wang T; Wang S; Xu Y; Shi L; Tang X; Su Q; Yu X; Yan L; Wan Q; Chen G; Gao Z; Wang G; Shen F; Luo Z; Zhang Y; Liu C; Wang Y; Hu R; Ye Z; Wu S; Deng H; Yang T; Li Q; Qin Y; Mu Y; Zhao J; Ning G; Bi Y; Xu Y; Wang W
    Metabolism; 2021 Nov; 124():154874. PubMed ID: 34517014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the Path of Mediterranean Diet, Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation towards 10-Year Cardiovascular Disease (CVD) Risk: The ATTICA Study 10-Year Follow-Up (2002-2012).
    George ES; Georgousopoulou EN; Mellor DD; Chrysohoou C; Pitsavos C; Panagiotakos DB
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease.
    Baars T; Gieseler RK; Patsalis PC; Canbay A
    Metabolism; 2022 May; 130():155179. PubMed ID: 35283187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review.
    Ismaiel A; Dumitraşcu DL
    Front Med (Lausanne); 2019; 6():202. PubMed ID: 31616668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort.
    Sharma D; Gotlieb N; Farkouh ME; Patel K; Xu W; Bhat M
    J Am Heart Assoc; 2022 Jan; 11(1):e022576. PubMed ID: 34927450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease].
    Kim HS; Cho YK
    Korean J Gastroenterol; 2017 Jun; 69(6):333-340. PubMed ID: 28637101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors.
    Mann JP; Carter P; Armstrong MJ; Abdelaziz HK; Uppal H; Patel B; Chandran S; More R; Newsome PN; Potluri R
    PLoS One; 2020; 15(10):e0241357. PubMed ID: 33108366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
    Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
    Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study.
    Chang Y; Ryu S; Sung KC; Cho YK; Sung E; Kim HN; Jung HS; Yun KE; Ahn J; Shin H; Wild SH; Byrne CD
    Gut; 2019 Sep; 68(9):1667-1675. PubMed ID: 30472683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study.
    Pastori D; Sciacqua A; Marcucci R; Del Ben M; Baratta F; Violi F; Pignatelli P;
    Intern Emerg Med; 2021 Nov; 16(8):2063-2068. PubMed ID: 33713286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.
    Cai J; Zhang XJ; Ji YX; Zhang P; She ZG; Li H
    Circ Res; 2020 Feb; 126(5):679-704. PubMed ID: 32105577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.
    Targher G; Bertolini L; Padovani R; Rodella S; Zoppini G; Pichiri I; Sorgato C; Zenari L; Bonora E
    J Hepatol; 2010 Oct; 53(4):713-8. PubMed ID: 20619918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.
    Chiriac S; Stanciu C; Girleanu I; Cojocariu C; Sfarti C; Singeap AM; Cuciureanu T; Huiban L; Muzica CM; Zenovia S; Nastasa R; Trifan A
    Can J Gastroenterol Hepatol; 2021; 2021():6696857. PubMed ID: 33505944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NAFLD and cardiovascular diseases: a clinical review.
    Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM
    Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review.
    Li XL; Sui JQ; Lu LL; Zhang NN; Xu X; Dong QY; Xin YN; Xuan SY
    Lipids Health Dis; 2016 Mar; 15():53. PubMed ID: 26965314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Link Between Non-Alcoholic Fatty Liver Disease and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Minhas AM; Usman MS; Khan MS; Fatima K; Mangi MA; Illovsky MA
    Cureus; 2017 Apr; 9(4):e1142. PubMed ID: 28484681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.